Emulate, Inc.
27 Drydock Ave
5th Floor
Boston
Massachusetts
02210
United States
Website: https://www.emulatebio.com/
38 articles with Emulate, Inc.
-
Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against SARS-CoV-2
10/29/2020
Agency-wide CRADA agreement also includes studies with Brain-Chip in Alzheimer’s disease, Intestine-Chip in microbiome health, and Liver-Chip in individualized toxicity responses
-
Emulate, Inc. Appoints Jim Corbett as Chief Executive Officer and Martin Madaus, PhD, as Executive Chairman
3/19/2020
Company Builds Leadership Team for Next Stage of Growth with Expanded Commercialization of Organs-on-Chips Product Suite
-
Emulate Achieves 150 User Installations of Zoë® Instrument as a Lab-Ready Organs-on-Chips Platform, Along With 3 Commercially Available Chips for Liver, Kidney, and Intestine
3/19/2020
Platform adopted by 10 of the top 25 biopharmaceutical companies, by U.S. governmental agencies, and by academic research centers worldwide
-
Emulate Publishes Results for Intestine-Chip Populated with Organoids; Data Demonstrates Superior Human-relevant Intestine Function than Organoids Alone
1/14/2020
Emulate’s Duodenum Intestine-Chip provides a robust system for preclinical drug assessment of drug transport, metabolism, and drug-drug interactions in the intestine
-
Liver-Chip Predicts Human Toxicity that was Undetected in Animal Studies for Drugs Halted in Clinical Trials
11/6/2019
Data published in Science Translational Medicine with Emulate’s Liver-Chip demonstrate robust reproducibility and diverse phenotypes of human liver toxicities and species-specific drug responses
-
Emulate, Inc. and INTENZE Products, Inc. Announce Collaboration to Use Organ-Chips to Study Tattoo Ink Safety Risks
6/18/2019
This collaboration marks the first time a tattoo company and a biotechnology & health company have collaborated for the advancement of safety testing and risk assessment of tattoo ink
-
To Infinity and Beyond! Emulate's Intestine-Chip Heads to the International Space Station
12/27/2018
Boston-based Emulate focuses on developing true-to-life biological models, sometimes dubbed organs-on-chips. Emulate’s proprietary Organ-Chips include lung, liver, brain, intestine and kidney, are made up of minuscule hollow channels lined with thousands of living human cells and tissue, all abou... -
Emulate, Inc. Awarded Grant to Use Intestine-Chip to Study Human GI Infections Aboard the International Space Station
12/18/2018
Emulate announced today that it has received a research grant to use the company’s Intestine-Chip to conduct experiments that will provide insights into the function of the intestinal barrier and its response to bacterial invasion in microgravity. Experiments will be conducted on the International Space Station and on Earth to analyze cellular interactions within the Intestine-Chip and to better understand the impact of bacterial challenges on gastrointestinal (GI) homeostasis
-
A recent survey by the Pew Research Center found that 57 percent of Americans surveyed thought it was appropriate to use genetically engineered animals to grow organs for human transplants.
-
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
-
There has been recent coverage of 3D bioprinting and how it has the potential to create a brave new world of printed organs to be used in biopharma research and maybe someday to even be used in organ transplants.
-
Boston-based Emulate closed on a Series C round worth $36 million.
-
Founders Fund Leads $36 Million Financing Round in Emulate, Inc.
6/19/2018
Emulate, Inc. announced that it has secured a $36 million Series C financing round
-
Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Side-by-Side on Organs-on-Chips Technology to Improve Prediction of Human Safety and Efficacy of Drug Candidates
5/16/2018
AstraZeneca is the first pharmaceutical company to work with Emulate to develop and embed its Organ-on-Chips technology in its laboratories.
-
Emulate, Inc. struck a deal with pharma giant AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit to embed its Organs-on-Chips technology within the laboratories of the IMED Drug Safety organization.
-
Emulate, Inc. Announces Strategic Partnership with Roche to Apply the ‘Human Emulation System’ as a Platform for Drug Discovery
2/20/2018
Scientists from Emulate and Roche form innovative partnership to use Organ-Chips for testing of efficacy and safety of new antibody therapeutics and combination therapies
-
Cedars-Sinai and Emulate, Inc. Advance Precision Medicine With Organs-on-Chips, Stem Cells
2/20/2018
Scientists at Cedars-Sinai and Emulate, Inc. are pioneering a Patient-on-a-Chip program to help predict which disease treatments would be most effective based on a patient's genetic makeup and disease variant—a new approach to precision medicine for improving patient care and health.
-
Emulate Awarded Grant To Fund Use Of Human Emulation System Aboard The International Space Station
6/20/2017
-
New Data From Emulate's Asthma-on-Chip Presented At American Thoracic Society Annual Meeting
5/23/2017
-
FDA Picks Boston's Emulate for its Organ-on-a-Chip Technology
4/12/2017